Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy

Yu, Dapeng; Zhang, Shuisheng; Feng, Alei; Xu, Dongjuan; Zhu, Qingshan; Mao, Yantao; Zhao, Yi; Lv, Yajuan; Han, Cuiping; Liu, Rujun; Tian, Yuan

doi:10.1097/md.0000000000015582

Cited by 71 publications

(55 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a recent meta-analysis, the methotrexate, doxorubicin, and cisplatin regimen remains the preferred option for osteosarcoma chemotherapy. 22 The most common grade 3/4 adverse event reported is neutropenia. 22 Ten of the 12 patients in our study were administered chemotherapy according to the NECO-95J protocol, which resulted in a good histological response, was comparable to induction chemotherapy, and had a favorable overall survival 23 (78.7%).…”

Section: Discussionmentioning

confidence: 99%

Outcomes of comprehensive treatment for primary osteosarcoma

et al. 2020

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate the clinical features and outcomes of osteosarcoma to identify prognostic factors and determine new strategies to improve overall survival. Patients and Methods: We retrospectively analyzed 12 cases of osteosarcoma treated at our hospital from 2012 to 2017. Tumor site, tissue type, stage, treatments, adverse effects, postoperative limb function, surgical margin, and final outcomes were evaluated. Results: All patients received chemotherapy, and 10 underwent wide resection. The Musculoskeletal Tumor Society scores were more than good in all cases, and the 3-year survival rate was 73.3%. Two patients are alive with disease, eight have remained disease-free, and two died of the disease. Three of the four recurrent cases involved the pelvis. Conclusion: The treatment of primary osteosarcoma with wide resection in our department, therefore, yielded favorable outcomes. However, improved treatment strategies are needed for pelvic and advanced cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of comprehensive treatment for primary osteosarcoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Mtx is one of the first-line chemotherapy drugs for OS, which inhibits the synthesis of tumor cells mainly by inhibiting dihydrofolate reductase (Yu et al, 2019;Zhang et al, 2020). Aln is the most important anti-bone resorber for the treatment of bone diseases (Vasikaran, 2001;Rogers et al, 2015).…”

Section: Evaluation Of Anti-tumor Effects In Vivomentioning

confidence: 99%

Locally Controlled Release of Methotrexate and Alendronate by Thermo-Sensitive Hydrogels for Synergistic Inhibition of Osteosarcoma Progression

Shan

Zhao

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Osteosarcoma (OS) is a serious primary bone malignant tumor that can easily affect children and adolescents. Chemotherapy is one of the important and feasible clinical treatment strategies for the treatment of OS at present, which is severely limited due to insufficient retention time, poor penetration ability, and serious side effects of current antitumor drug preparations. In this work, a novel injectable thermo-sensitive hydrogel (mPEG 45-PLV 19) loaded with methotrexate and alendronate, and the sustained release at the tumor site synergistically inhibited the progression of OS. The mPEG 45-PLV 19 shows excellent physical and chemical properties. Compared with other treatment groups, the in vivo treatment of gel+ methotrexate + alendronate effectively inhibited the growth of tumor. More importantly, it significantly reduced bone destruction and lung metastasis caused by OS. Therefore, this injectable thermo-sensitive hydrogel drug delivery system has broad prospects for OS chemotherapy.

show abstract

“…It is also capable of inducing senescence in solid tumor depending upon concentrations administered (Kozhukharova et al, 2018). In OS treatment, DOXO is administered intravenously along with other chemotherapeutic drugs including methotrexate (MAP) and cisplatinum (Yu et al, 2019). In vitro studies assessing the effect of DOXO in human OS cell lines showed that cellular metabolic activity and growth of U2OS spheroids decrease after 24 h DOXO drug exposure, following endocytosis (Baek et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Development of Natural-Based Bone Cement for a Controlled Doxorubicin-Drug Release

Dewhurst

Scalzone

Buckley

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Osteosarcoma (OS) accounts for 60% of all global bone cancer diagnoses. Intravenous administration of Doxorubicin Hydrochloride (DOXO) is the current form of OS treatment, however, systemic delivery has been linked to the onset of DOXO induced cardiomyopathy. Biomaterials including calcium phosphate cements (CPCs) and nanoparticles (NPs) have been tested as localized drug delivery scaffolds for OS cells. However, the tumor microenvironment is critical in cancer progression, with mesenchymal stem cells (MSCs) thought to promote OS metastasis and drug resistance. The extent of MSC assisted survival of OS cells in response to DOXO delivered by CPCs is unknown. In this study, we aimed at investigating the effect of DOXO release from a new formulation of calcium phosphate-based bone cement on the viability of OS cells cocultured with hMSC in vitro. NPs made of PLGA were loaded with DOXO and incorporated in the formulated bone cement to achieve local drug release. The inclusion of PLGA-DOXO NPs into CPCs was also proven to increase the levels of cytotoxicity of U2OS cells in mono-and coculture after 24 and 72 h. Our results demonstrate that a more effective localized DOXO delivery can be achieved via the use of CPCs loaded with PLGA-DOXO NPs compared to CPCs loaded with DOXO, by an observed reduction in metabolic activity of U2OS cells in indirect coculture with hMSCs. The presence of hMSCs offer a degree of DOXO resistance in U2OS cells cultured on PLGA-DOXO NP bone cements. The consideration of the tumor microenvironment via the indirect inclusion of hMSCs in this study can act as a starting point for future direct coculture and in vivo investigations.

show abstract

Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy

Abstract: Supplemental Digital Content is available in the text

Cited by 71 publications

References 42 publications

Outcomes of comprehensive treatment for primary osteosarcoma

Outcomes of comprehensive treatment for primary osteosarcoma

Locally Controlled Release of Methotrexate and Alendronate by Thermo-Sensitive Hydrogels for Synergistic Inhibition of Osteosarcoma Progression

Development of Natural-Based Bone Cement for a Controlled Doxorubicin-Drug Release

Contact Info

Product

Resources

About